TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19054832
Drug: Topical anaesthetic
Normalized name: Topical anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthetic eye-drops only
Study: 14978663
Drug: High-dose D-penicillamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose D-penicillamine (822 mg daily)
Study: 14978663
Drug: Low-dose D-penicillamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose D-penicillamine (120 mg every other day)
Study: 12202467
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 mg or more)
Study: 7977218
Drug: Outpatient day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient day treatment program (28-day duration)
Study: 2513172
Drug: Hypercaloric nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypercaloric nutrition (32 +/- 3.8 kcal/kg/d and 1.23 g/kg/d of protein)
Study: 31943807
Drug: Family-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-focused therapy (FFT)
Study: 19672568
Drug: EpiCor (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: EpiCor (500 mg of a dried, modified Saccharomyces cerevisiae oral fermentation product)
Study: 7803885
Drug: Prophylactic agents
Normalized name: Caries prophylactic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic agents (general)
Study: 4311189
Drug: Corticotrophin gel
Normalized name: corticotropin Injectable Solution [ACTH Gel]
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Corticotrophin gel
Study: 16442045
Drug: Laser lipolysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser lipolysis followed by biweekly treatments with the Tri-active system
Study: 11777511
Drug: Dexamethasone 16
Normalized name: dexamethasone 16 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 16 mg
Study: 12538199
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (3.5-5 mg) plus ketamine (20/30 mg)
Study: 12538199
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (3.5-5 mg)
Study: 10396749
Drug: Type A
Normalized name: HLA type A IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type A botulinum toxin (AGN 191622) - 1 unit (group L)
Study: 2405653
Drug: Intraperitoneal (IP)
Normalized name: Intraperitoneal Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal (IP) cephalothin (250 mg/L) and tobramycin (8 mg/L)
Study: 2405653
Drug: Oral ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ofloxacin (400 mg loading followed by 300 mg daily)
Study: 2405653
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ofloxacin (400 mg followed by 300 mg daily) and rifampicin (300 mg daily)
Study: 6252744
Drug: FK 33-824
Normalized name: FK-960
DrugBank: FK-960 (DB06465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK 33-824 (0.5 mg im)
Study: 6252744
Drug: Naloxone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (4 mg iv)
Study: 31227978
Drug: Capsule debridement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule debridement during CIED replacement
Study: 31227978
Drug: No capsule
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No capsule debridement during CIED replacement
Study: 24117002
Drug: Iodine supplementation
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine supplementation (150 μg of potassium iodide daily) - Group A
Study: 21091414
Drug: Physiotherapy interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physiotherapy interventions including daily supervised, progressive exercises until discharge and a postoperative exercise booklet on discharge
Study: 10793604
Drug: Cold sensation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold sensation from ethyl chloride spray
Study: 8619185
Drug: Dacron patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacron patch angioplasty
Study: 8619185
Drug: Vein patch
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vein patch angioplasty
Study: 2906174
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg once daily
Study: 7818116
Drug: Intravenous oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous oxycodone
Study: 31014267
Drug: Moderate to
Normalized name: GenTeal Moderate to Severe Ophthalmic Gel Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate to vigorous physical activity (MVPA) split (≥45 min average daily MVPA)
Study: 27987595
Drug: Twice-daily thoracic
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily thoracic radiotherapy (TRT) (45 Gy/30 fractions)
Study: 27987595
Drug: Once-daily thoracic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily thoracic radiotherapy (TRT) (42 Gy/15 fractions)
Study: 27987595
Drug: First chemotherapy-course
Normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First chemotherapy-course
Study: 20522615
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (LD) pantoprazole (0.3 mg/kg)
Study: 20522615
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose (MD) pantoprazole (0.6 mg/kg)
Study: 20522615
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (HD) pantoprazole (1.2 mg/kg)
Study: 20522615
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose (MD) pantoprazole (0.6 mg/kg) for EE
Study: 20522615
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (HD) pantoprazole (1.2 mg/kg) for EE
Study: 18847151
Drug: Nebulized steroid
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized steroid fluticasone (Flixotide Nebules)
Study: 18847151
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (nebulized fluticasone and intravenous methylprednisolone)
Study: 18847151
Drug: Flixotide treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flixotide treatment arm
Study: 2106256
Drug: [1-13C]acetate infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: [1-13C]acetate infusion
Study: 2106256
Drug: [2-13C]acetate infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: [2-13C]acetate infusion
Study: 2106256
Drug: [1-13C]acetate infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: [1-13C]acetate infusion during exogenous glucose infusion
Study: 2106256
Drug: [2-13C]acetate infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: [2-13C]acetate infusion during exogenous glucose infusion
Study: 2106256
Drug: [1-14C]acetate infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: [1-14C]acetate infusion
Study: 7030373
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nifedipine and propranolol
Study: 7030373
Drug: Propranolol (50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (50% dosage reduction)
Study: 30789934
Drug: Motivational patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational patient education including motivational communication techniques and repeated training until correct administration.
Study: 30789934
Drug: Standard feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard feedback on erroneous administration steps without further assessment or reinforced training.
Study: 30193275
Drug: Immediate reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate reduction to 0.4 mg of nicotine per gram of tobacco cigarettes
Study: 30193275
Drug: Gradual reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual reduction from 15.5 mg to 0.4 mg of nicotine per gram of tobacco cigarettes
Study: 30193275
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (maintenance on 15.5 mg of nicotine per gram of tobacco cigarettes)
Study: 26797774
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose betahistine (2 × 24 mg daily)
Study: 26797774
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose betahistine (3 × 48 mg daily)
Study: 16257815
Drug: Once-weekly alendronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly alendronate 70 mg oral solution
Study: 10499773
Drug: TA 1200
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TA 1200 (1200 mg of thioctic acid)
Study: 10499773
Drug: TA 600
Normalized name: Xenleta 600mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: TA 600 (600 mg of thioctic acid)
Study: 8688994
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (R)
Study: 8688994
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (T)
Study: 17621203
Drug: Active exercise
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active exercise and education using a cognitive behavioral therapy (CBT) approach, delivered in eight 2-hour group sessions over 6 weeks by physiotherapists.
Study: 15848558
Drug: 0.75 g
Normalized name: Allantoin 0.75 g in 75 g TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 g MMF twice a day with SRL
Study: 15848558
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g MMF twice a day with SRL
Study: 15848558
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g MMF twice a day with SRL
Study: 15848558
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g MMF twice a day with CsA
Study: 12364424
Drug: RAI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAI plus lithium for 6 days starting on the day of RAI therapy (G2)
Study: 11803607
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (LPD) with 0.6 g of protein and 35 kcal/kg/day, recombinant human erythropoietin (rHuEPO) at a dose of 40 U kg/week, and keto acids (KA) 100 mg/kg/day (Group I)
Study: 9667297
Drug: 0.0625% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0625% bupivacaine with 2.5 microg/ml fentanyl
Study: 517720
Drug: Ethamsylate 1000
Normalized name: ethamsylate
DrugBank: Etamsylate (DB13483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethamsylate 1000 mg intravenously before induction of anaesthesia
Study: 30620642
Drug: Standard exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard exercise guidelines (0.5 g CHO/kg/h when glucose <8 mmol/L)
Study: 29540273
Drug: Usual diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual diet and placebo pills (n = 29)
Study: 29540273
Drug: Usual diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual diet and antioxidant supplements (n = 29)
Study: 29540273
Drug: Antioxidant-rich foods
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant-rich foods closely matched to antioxidant content of supplements and placebo (n = 30)
Study: 11911557
Drug: 5-day gatifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day gatifloxacin 400 mg once daily
Study: 11911557
Drug: 10-day gatifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day gatifloxacin 400 mg once daily
Study: 11911557
Drug: 10-day amoxicillin/clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day amoxicillin/clavulanate 875 mg twice daily
Study: 10419989
Drug: Dark green,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dark green, leafy vegetables with fat (10 g/100 g)
Study: 7869865
Drug: Conservative management;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative management; details on dosage and duration not specified.
Study: 7869865
Drug: Surgery; details
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery; details on dosage and duration not specified.
Study: 2073672
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg q.p.m. (doubled if LDL > 140 mg/dl after 6 weeks)
Study: 6459256
Drug: Tizanidine (5-Chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tizanidine (5-Chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole), administered t.i.d. for 7 days
Study: 6459256
Drug: Diazepam, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam, administered t.i.d. for 7 days
Study: 29067761
Drug: Therapies that
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapies that improve outcomes in heart failure with reduced ejection fraction (HFrEF)
Study: 25733635
Drug: High-flavanone (305
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flavanone (305 mg) 100% orange juice
Study: 25733635
Drug: Low-flavanone (37
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flavanone (37 mg) orange-flavored cordial (500 mL)
Study: 23032168
Drug: Meningococcal ACWY-tetanus
Normalized name: meningococcal ACWY, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal ACWY-tetanus toxoid conjugate vaccine (ACWY-TT group; n = 231)
Study: 23032168
Drug: Licensed meningococcal
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed meningococcal ACWY polysaccharide vaccine (Men-PS group; n = 78)
Study: 18435692
Drug: Psychological characteristics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological characteristics assessed by a self-administered questionnaire
Study: 12381039
Drug: Virtual-reality (VR)
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Virtual-reality (VR) treatment
Study: 14565594
Drug: Alendronate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (10 mg/day) plus calcium (1000 mg/day)
Study: 7762531
Drug: Arabica coffee
Normalized name: arabica coffee oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arabica coffee oil (2 g daily)
Study: 7762531
Drug: Robusta coffee
Normalized name: Robusta Coffee Bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robusta coffee oil (2 g daily)
Study: 25421252
Drug: Capecitabine alone
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine alone (500-825 mg/m2/bid, days 1-21)
Study: 25421252
Drug: Capecitabine plus
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine plus Valproic acid (oral daily, day -14 to 21, target serum level 50-100 microg/ml)
Study: 7598669
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) - 10-session treatment package including progressive relaxation, rational thinking, and pain coping strategies.
Study: 2358617
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg Zn daily for 12 months
Study: 2358617
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Zn daily for 12 months
Study: 475632
Drug: One-half isotonic
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-half isotonic saline solution
Study: 28616923
Drug: Tramadol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 0.5 mg/kg (TRM1)
Study: 28616923
Drug: Tramadol 1
Normalized name: tramadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 1 mg/kg (TRM2)
Study: 28616923
Drug: Tramadol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 1.5 mg/kg (TRM3)
Study: 25825006
Drug: Web-based monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based monthly monitoring with the Childhood Asthma Control Test (ACT)
Study: 25825006
Drug: 4-monthly monitoring
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4-monthly monitoring of FENO
Study: 24068825
Drug: Quetiapine 150
Normalized name: quetiapine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine 150 mg XL for 7 days
Study: 12699266
Drug: Pretreatment with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretreatment with GnRH agonists before IVF cycle initiation
Study: 11092289
Drug: Nateglinide 120
Normalized name: nateglinide 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide 120 mg before meals
Study: 16827766
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg three times a day
Study: 11092289
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (nateglinide + metformin)
Study: 9170525
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus injection of 5 mg azasetron before and 8 hours after chemotherapy
Study: 9170525
Drug: Standard group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard group receiving intravenous bolus injection of 10 mg azasetron once a day
Study: 2971310
Drug: Celiprolol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (400 mg once a day)
Study: 30313092
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (TIVA) (propofol and remifentanil)
Study: 25913923
Drug: IR/ER HB/APAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: IR/ER HB/APAP (7.5/325 mg) fixed-dose combination analgesic agent, initial dose of 22.5/975 mg on day 1, followed by 15/650 mg every 12 hours for up to 35 days.
Study: 25913923
Drug: IR/ER HB/APAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: IR/ER HB/APAP (7.5/325 mg) fixed-dose combination analgesic agent.
Study: 24469870
Drug: N-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-3 polyunsaturated fatty acids (Omacor) 1 g daily
Study: 24469870
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard therapy + 75 mg acetylsalicylic acid + 75 mg clopidogrel)
Study: 19048591
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors alone or associated with corticosteroids
Study: 1959498
Drug: Tetrabamate (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrabamate (900 mg/day)
Study: 1959498
Drug: Lorazepam (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (4.5 mg/day)
Study: 6753116
Drug: Pirenzepine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (100 mg/daily)
Study: 25855267
Drug: Extended-release carbidopa-levodopa
Normalized name: carbidopa / levodopa Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release carbidopa-levodopa (ER CD-LD) 97.5 mg-390 mg
Study: 25855267
Drug: Immediate-release carbidopa-levodopa
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release carbidopa-levodopa (IR CD-LD) 25 mg-100 mg
Study: 25855267
Drug: Sustained-release carbidopa-levodopa
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release carbidopa-levodopa (CR CD-LD) 25 mg-100 mg
Study: 25855267
Drug: Carbidopa-levodopa-entacapone (Stalevo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbidopa-levodopa-entacapone (Stalevo) 25 mg-100 mg-200 mg
Study: 23942038
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of levocetirizine
Study: 23942038
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose of levocetirizine
Study: 19675538
Drug: Catecholamine depletion
Normalized name: Allogeneic thymocyte-depleted thymus tissue-agdc
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catecholamine depletion (CD) achieved by oral administration of alpha‐methyl‐paratyrosine (AMPT)
Study: 17877165
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A + C meningococcal polysaccharide vaccine (100 microg)
Study: 17877165
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A meningococcal polysaccharide vaccine (50 microg)
Study: 17877165
Drug: Typhoid Vi
Normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typhoid Vi polysaccharide vaccine (30 microg)
Study: 2902263
Drug: Edmonston-Zagreb (EZ)
Normalized name: measles virus vaccine live, Enders' attenuated Edmonston strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) / varicella-zoster virus vaccine live (Oka-Merck) strain Injection [ProQuad]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edmonston-Zagreb (EZ) measles vaccine, 40,000 plaque forming units
Study: 2902263
Drug: Schwarz measles
Normalized name: measles virus vaccine live, attenuated Schwarz strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schwarz measles vaccine, 6000 tissue culture infectious units
Study: 2902263
Drug: Edmonston-Zagreb (EZ)
Normalized name: measles virus vaccine live, Enders' attenuated Edmonston strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) / varicella-zoster virus vaccine live (Oka-Merck) strain Injection [ProQuad]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edmonston-Zagreb (EZ) measles vaccine
Study: 31204129
Drug: Single-dose Custodiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose Custodiol histidine‐tryptophan‐ketoglutarate
Study: 16446183
Drug: Fondaparinux administered
Normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fondaparinux administered 8 +/- 2 hours after surgery